Your Good Partner in Biology Research

  1. Home
  2. 抗体
  3. 多克隆抗体
  4. SLC22A2 Antibody

SLC22A2 Antibody

  • 货号：
    CSB-PA021453GA01HU
  • 规格：
    ￥3,900
  • 其他：

产品详情

  • Uniprot No.：
    O15244
  • 基因名：
    SLC22A2
  • 别名：
    SLC22A2 antibody; OCT2Solute carrier family 22 member 2 antibody; Organic cation transporter 2 antibody; hOCT2 antibody
  • 宿主：
    Rabbit
  • 反应种属：
    Human,Mouse,Rat
  • 免疫原：
    Human SLC22A2
  • 免疫原种属：
    Homo sapiens (Human)
  • 抗体亚型：
    IgG
  • 纯化方式：
    Antigen Affinity purified
  • 浓度：
    It differs from different batches. Please contact us to confirm it.
  • 保存缓冲液：
    PBS with 0.02% Sodium Azide, 50% Glycerol, pH 7.3. -20°C, Avoid freeze / thaw cycles.
  • 产品提供形式：
    Liquid
  • 应用范围：
    ELISA,WB
  • Protocols：
  • 储存条件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 货期：
    Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

产品评价

靶点详情

  • 功能：
    Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamine, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, cisplatin and oxaliplatin. Cisplatin may develop a nephrotoxic action. Transport of creatinine is inhibited by fluoroquinolones such as DX-619 and LVFX. This transporter is a major determinant of the anticancer activity of oxaliplatin and may contribute to antitumor specificity.
  • 基因功能参考文献：
    1. African-specific promoter polymorphisms can cause a decrease in the SLC22A2 gene expression levels in vitro, which in turn, may influence the pharmacokinetic profiles of cationic drugs. PMID: 29624501
    2. OCT2-altered expression in primary and metastatic cancer cells. PMID: 29794161
    3. Circ2174 has sequence complementarity to miR149 which can target Oct-2.These data suggest a mechanism whereby circ2174 can act as a sponge to regulate the expression of miR149, and thereby modulate Oct-2 and interleukin-16 signaling pathways in cholangiocarcinoma. PMID: 30168369
    4. SLC22A2 deletion is associated with motor speech disorders, and language delays. PMID: 28767196
    5. Pazopanib inhibits OCT2, MATE1 and MATE2-K, which are involved in cisplatin secretion into urine, potentiating cisplatin toxicity. PMID: 27178732
    6. The combination of ENT1, MATE1 and OCT2 SNPs may serve as a predictive and prognostic marker in metastatic colorectal carcinoma patients treated with TAS-102. PMID: 28992563
    7. This study of SLC22A2 contributes in filling the gap that exists with regards to genetic information about important variations in organic cation transporter genes for the indigenous populations of South Africa. PMID: 27828777
    8. Oct2 and Bob1 are very reliable in determining B cell lineage in the absence of expression of other pan-B cell markers PMID: 27319306
    9. Formononetin prevents cisplatin-induced acute kidney injury by targeting Oct2/TP53 in the kidney. PMID: 28414026
    10. OCT2 polymorphisms were associated with hematological toxicity in non-small cell lung cancer patients. PMID: 27590272
    11. An association was found between SNPs in OCT2 transporter and lack of metformin response in type 2 diabetes mellitus patients. PMID: 27609360
    12. Seventeen of the variants observed in the SLC22A2 gene of the Xhosa population were specific to/or occurred at a higher frequency in African populations or populations with a recent connection to the African continent. PMID: 26674735
    13. We noted a statistically significant association between the nonsynonymous SNP rs316019(SLC22A2) and cisplatin-induced ototoxicity, in that the T allele occurred more frequently in patients who experienced no ototoxicity from cisplatin treatment. PMID: 25823781
    14. the loss-of-function variant OCT2-T201M (rs145450955) contribute to changes in insulin resistance and beta cell activity in patients with T2D treated with metformin. PMID: 25662675
    15. The 808G>T variant of SLC22A2 improves the metformin long-term glucose-lowering effect in Chinese type 2 diabetics. PMID: 25573751
    16. functional amino acid residues involved in polyamine and agmatine transport by human organic cation transporter 2 PMID: 25019617
    17. The functional OCT2 Ser270Ala polymorphism is significantly associated with abstinence among treatment-seeking smokers. PMID: 25143296
    18. Clopidogrel/clopidogrel carboxylate are weak inhibitors of OCT2. PMID: 24530383
    19. The genetic polymorphisms in OCT2, AQP2, AQP9 and TMEM205 may contribute to chemotherapy response in lung cancer patients. PMID: 24643204
    20. In chemotherapy for oesophageal cancers, cisplatin-induced nephrotoxicity seems to be unaffected by SLC22A2 polymorphism PMID: 24102360
    21. results suggest that high levels of OCT2 indicate severe invasion, but also better prognosis in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy PMID: 24427340
    22. ADMA and L-arginine are substrates of human CAT2A, CAT2B, OCT2 and MATE1. Transport kinetics of CAT2A, CAT2B, and OCT2 indicate a low affinity, high capacity transport, which may be relevant for renal and hepatic elimination of ADMA or L-arginine PMID: 23864433
    23. The results confirmed that OAT1, OAT3, OCT2, MATE1, and MATE2-K were coexpressed in tubular epithelial cells. PMID: 23630107
    24. hOCT2 does not apperar to contribute significantly to fluoroquinolone disposition. PMID: 23545524
    25. Cellular uptake of oxaliplatin increases by 16- to 35-fold in cells overexpressing OCT2, a process that is associated with increased DNA platination and oxaliplatin-induced cytotoxicity. PMID: 23776246
    26. SLC22A2 single nucleotide polymorphisms (SNPs), rs3127573 and rs316009, were genotyped in 1,142 ESRD patients receiving renal transplantation. Neither SNP was associated with GF PMID: 23341218
    27. expression and prognostic impact of SOX2, OCT4, Nanog and Nestin in nasopharyngeal carcinoma PMID: 23424657
    28. The 808G>T single-nucleotide polymorphism in OCT2 ameliorated cisplatin-induced nephrotoxicity without alteration of disposition, whereas the rs2289669 G>A single-nucleotide polymorphism in MATE1 had no effect on cisplatin toxicity. PMID: 22569819
    29. results suggested that SLC22A2 gene polymorphism 808 G/T and cimetidine could attenuate cisplatin nephrotoxicity in Chinese cancer patients PMID: 22525860
    30. Conserved cysteines in the human organic cation transporter 2 (hOCT2), namely the six cysteines in the long extracellular loop (loop cysteines) and C474 in transmembrane helix 11, are important for plasma membrane targeting. PMID: 22573376
    31. tryptophan can serve as one of the endogenous substrate for the OCT2 as well as a biomarker candidate indicating the variability of the transport activity of OCT2. PMID: 22590580
    32. OCT2 plays a decisive role in the renal secretion of creatinine. This process can be inhibited by OCT2 substrates, which impair the usefulness of creatinine as a marker of renal function. PMID: 22223530
    33. Data show that the cysteines of the large extracellular loop are important to enable correct folding, oligomeric assembly, and plasma membrane insertion of organic cation transporter 2 (hOCT2). PMID: 22085643
    34. hOCT2 interacts with LAPTM4A in lysosomes and late endosomes and regulates endocytotic recruitment. PMID: 21553234
    35. Our findings suggest that SLC22A2 could be a susceptibility gene for aspirin intolerance in asthmatics. PMID: 21346370
    36. The results suggest that agmatine disposition may be influenced by hOCT2 and hMATE1, two transporters critical in the renal elimination of xenobiotic compounds. PMID: 21128598
    37. The hSLC22A2 drug transporter is a critical determinant in the uptake and cytotoxicity of various platinum compounds, particularly oxaliplatin. PMID: 20067471
    38. This study showed that coordinate function of MATE1 with OCT2 likely contributes to the vectorial renal elimination of organic cationic drugs and that altered activity of MATE1 should be considered as a determinant of renal cationic drug elimination. PMID: 20053795
    39. The human organic cation transporter (hOCT2) recognizes the degree of substrate ionization PMID: 11953440
    40. cDNA coding hOCT2-A was isolated from human kidney. an alternatively spliced variant of hOCT2 with an insertion of 1169 bp. open reading frame encodes 483-amino acid protein with 81% amino acid identity with hOCT2. PMID: 12089365
    41. polymorphisms in kidney exhibit altered function PMID: 12142729
    42. inhibited by PI3K and PKA and activated by a CaM-dependent signaling pathway PMID: 12388397
    43. OCT2 efficiently translocates agmatine and must be considered for the control of agmatine levels. PMID: 12538837
    44. Ranitidine and famotidine elicited differential inhibitory activities on SLC22A2. PMID: 16141367
    45. uptake of cis-platin is mediated by hOCT2 in renal proximal tubules; cis-platin with other substrates that compete for hOCT2 offers an effective option to decrease nephrotoxicity in the clinical setting. PMID: 16314463
    46. N-glycosylation of OCT2 has a profound effect on plasma membrane expression, substrate affinity, and maximum rate of substrate transport PMID: 16368738
    47. OCT1 and OCT2 are major determinants of the anticancer activity of oxaliplatin and may contribute to its antitumor specificity. PMID: 16951202
    48. data demonstrate that cysteine 474 of OCT2 is exposed to the aqueous milieu of the cleft and contributes to forming a pathway for organic cation transport PMID: 16990275
    49. This study further suggests a function of OCT2 in blood pressure homeostasis and points to the potential role of the transporter in the development of essential hypertension. PMID: 17060063
    50. The results suggest that hOCT2 and hMATE1 mediate paraquat transport in the kidney. PMID: 17495125

    显示更多

    收起更多

  • 亚细胞定位：
    Membrane; Multi-pass membrane protein.
  • 蛋白家族：
    Major facilitator (TC 2.A.1) superfamily, Organic cation transporter (TC 2.A.1.19) family
  • 组织特异性：
    Mainly expressed in kidney. Localized at the luminal membrane and basolateral membrane of kidney distal tubule and proximal tubules. To a lower extent, expressed in neurons of the cerebral cortex and in various subcortical nuclei (at protein levels). Also
  • 数据库链接：

    HGNC: 10966

    OMIM: 602608

    KEGG: hsa:6582

    STRING: 9606.ENSP00000355920

    UniGene: Hs.436385